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Abstract Mutational acquired resistance is a major challenge
in cancer therapy. Somatic tumours harbouring some onco-
genic mutations are characterised by a high mortality rate.
Surprisingly, preclinical evaluation methods do not show
clearly resistance of mutated cancers to some drugs. Here,
we implemented Raman spectral imaging to investigate the
oncogenic mutation resistance to epidermal growth factor re-
ceptor targeting therapy. Colon cancer cells with and without
oncogenic mutations such asKRAS and BRAFmutations were
treated with erlotinib, an inhibitor of epidermal growth factor
receptor, in order to detect the impact of these mutations on
Raman spectra of the cells. Clinical studies suggested that
oncogenic KRAS and BRAF mutations inhibit the response
to erlotinib therapy in patients, but this effect is not observed
in vitro. The Raman results indicate that erlotinib induces
large spectral changes in SW-48 cells that harbour wild-type
KRAS and BRAF. These spectral changes can be used as a
marker of response to therapy. HT-29 cells (BRAF mutated)
and SW-480 cells (KRAS mutated) display a smaller and no
significant response, respectively. However, the erlotinib
effect on these cells is not observed when phosphorylation
of extracellular-signal-regulated kinase and AKT is monitored
by Western blot, where this phosphorylation is the conven-
tional in vitro test. Lipid droplets show a large response to
erlotinib only in the case of cells harbouring wild-type
KRAS and BRAF, as indicated by Raman difference spectra.
This study shows the great potential of Raman spectral imag-
ing as an in vitro tool for detecting mutational drug resistance.
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Introduction
Cancer is one of the leading causes of death worldwide.
Statistics from the World Health Organization indicate that
8.2 million cases of cancer death were registered in 2012
[1]. This high number of cancer deaths is due to the failure
of many therapeutic strategies to suppress tumour progression.
Some oncogenic mutations render tumours aggressive, which
is accompanied by poor prognosis and a decreased response to
therapy [2–4]. Therefore, researchers in drug development are
competing to find new potent anticancer drugs that can over-
come the mutational drug resistance. Hundreds of new anti-
cancer drugs appear each year. To evaluate their potencies,
they are studied in a series of in vitro and in vivo preclinical
tests. The promising candidates are then proceeded to clinical
trials, to be tested on human cancer patients [5]. However,
preclinical methods do not predict the resistance of some on-
cogenic mutations to therapy, which is later detected in many
clinical studies. For instance, inhibitors of epidermal growth
factor receptor (EGFR) showed great therapeutic potential in
solid tumour suppression [6]. However, some of them failed in
patients with KRAS-mutated cancers [7].
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Owing to the overexpression of EGFR in many cancers,
targeting EGFR is one of the effective strategies to suppress
tumours in advanced stages [6,8]. EGFR is a transmembrane
protein with extracellular, transcellular, and intracellular do-
mains. It is a member of the ERBB family of receptors. Upon
binding of a ligand such as epidermal growth factor (EGF),
EGFR dimerises with other homologous members of the
ERBB receptors, which promotes phosphorylation of the in-
tracellular tyrosine kinase (TK) domain, which in turn stimu-
lates cell cycle progression as shown in Fig. 1. Erlotinib
(Tarceva) is a small molecule that inhibits the phosphorylation
of the EGFR TK domain. It blocks downstream signalling
transduction and tumour progression [9]. It is clinically ap-
proved by the US Food and Drug Administration and the
European Medicines Agency for the treatment of advanced
non-small-cell lung, and pancreatic cancers [10–15].
Erlotinib is still in clinical trials for the treatment of colon
cancer [16].
RAS is a membrane-anchored guanosine triphosphatase
protein [17]. It controls multiple downstream signalling path-
ways and acts as an on/off signalling switch (Fig. 1). Activated
EGFR sets RAS to on mode, which in turn activates multiple
effector proteins such as rapidly accelerated fibrosarcoma
(RAF), phosphatidylinositiol 3-kinase (PI3K), TIAM,
phospholipase Cε (PCLε), and RAL for cell proliferation
and survival [17–19]. In the case of EGFR inhibition, RAS
remains in off mode, and the cell cycle is arrested [20].
However, mutated RAS is chronically switched to on mode,
and it becomes independent of EGFR activation. Therefore,
RAS-mutated tumours are aggressive, invasive, and metasta-
tic. Moreover, it is accompanied by a decreased response to
EGFR-inhibition therapy [4,7,17,18,21–25]. KRAS mutation
accounts for 86 % of all RAS mutations [26]. It is commonly
found in the most deadly cancer types: lung (33 %), colon
(40 %), and pancreatic (90 %) cancers [27,28]. KRAS muta-
tion also is reported to be predictive for poor prognosis and
low survival rate in cancer [22,25,29].
RAF is one of the well-identified RAS effector proteins,
with serine/threonine kinase activity [17]. RAF is activated by
binding with the active form of RAS, which subsequently
stimulates the mitogen-activated protein kinase–extracellu-
lar-signal-regulated kinase (ERK) pathway proteins through
a cascade of autophosphorylation events towards cell prolif-
eration (Fig. 1) [30]. BRAFmutation occurred in up to 80% of
skin cancers and 5-10 % of colon cancers [31]. In addition,
BRAFmutation is accompanied by an elevated kinase activity,
which increases ERK phosphorylation [32,33]. Clinical stud-
ies showed that cancer patients with BRAF mutation have a
relatively poor prognosis [25,34].
Oncogenic mutations are commonly detected by DNA se-
quencing and methods based on polymerase chain reaction
[35,36]. In vitro assessment of drug effects is done separately
by cytotoxicity assays [5]. Although, some in vivo methods
such as genetically engineered cancer models revealed prom-
ising results in detecting drug resistance to mutations [37,38],
they still have some drawbacks, such as requiring a long time
and unpredictability of tumour formation [39]. To the best of
our knowledge, no in vitro method has reported so far the
impact of oncogenic mutations on response to EGFR molec-
ularly targeted therapy.
Raman micro-spectroscopic imaging is an emerging tech-
nique in biomedical research. Raman spectroscopy can mea-
sure biological samples in an aqueous physiological environ-
ment. It is a label-free, non-invasive technique with high
spectral/lateral resolution and great reproducibility [40–43].
Raman spectral imaging can classify cancerous human tissues
[44,45]. It can be used for imaging of single cells and charac-
terisation of subcellular components [46–50]. Furthermore,
Raman imaging can be conducted to monitor drug uptake
and its effect on single cells [51–57]. In our previous work
we investigated the distribution and metabolism of erlotinib in
SW-480 colon cancer cells using its unique –C≡C– band at
2100 cm−1, which is used as a marker band for erlotinib
localisation [53].
Here, we implemented Raman imaging coupled with hier-
archical cluster analysis (HCA) to monitor the response of
colon cancer cells to erlotinib therapy. We report in vitro ev-
idence that detects the effect of oncogenic KRAS and BRAF
mutations on the cellular response to erlotinib. The Raman
results show that colon cancer cells experience a large spectral
response to erlotinib, but colon cancer cells expressing onco-
genic BRAF or KRAS mutations experience small or no rele-
vant effects, respectively. Furthermore, the largest effect is
observed in lipid droplets of cancer cells harbouring wild-
type BRAF and KRAS that were treated with erlotinib.
Fig. 1 Epidermal growth factor receptor (EGFR)–RAS downstream
signalling cascade
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Material and methods
Cell culture
The colon cancer cell lines SW-48, HT-29, and SW-480 were
purchased from American Type Culture Collection. Cells
were cultured in Dulbecco’s modified Eagle’s medium (Life
Technologies, Darmstadt, Germany) supplemented with 10 %
fetal bovine serum (Life Technologies, Darmstadt, Germany),
2 mM l-glutamine, and 5% penicillin–streptomycin, and were
incubated at 37 °C in a 10 % CO2 atmosphere. Cells were
subcultured to 80 % confluence, detached by trypsin–EDTA
(0.25 %) (Gibco trypsin solution, Life Technologies,
Darmstadt, Germany), centrifuged at 1500 rpm for 3 min
and diluted to 10 %, then seeded again in culture medium.
Raman measurements were performed on cells grown on
CaF2 windows (Korth Kristalle, Kiel, Germany) to avoid
Raman scattering from regular glass slides. Cells were incu-
bated with erlotinib (Tarceva; Roche, Switzerland) at
10 μg/ml at 37 °C in 10 % CO2 for 12 h. Subsequently, cells
were fixed in 4 % paraformaldehyde (VWR International,
Darmstadt, Germany) and then submerged in phosphate-
buffered saline (Life Technologies, Darmstadt, Germany).
Confocal Raman microscopy
Cancer cells were measured with an alpha300 AR confocal
Raman microscope (WITec, Ulm, Germany) as described pre-
viously [45,50,53]. Briefly, the setup excitation source was a
frequency-doubled Nd:YAG laser of 532 nm (CrystaLaser,
Reno, NV, USA) with an output power of around 40 mW. The
laser radiation was coupled into a Zeiss microscope through a
wavelength-specific single-mode optical fibre. An achromatic
lens used as a collimator for the laser beam, and a holographic
band-pass filter focused the beam on the sample through a
Nikon NIR APO (×60/1.00 numerical aperture) water immer-
sion objective. The sample was located on a piezoelectrically
driven microscope scanning stage, which has an x,y resolution
of 3 nm and a z resolution of 0.3 nm. Raman back-scattered light
was collected through a microscopic objective and passed
through a holographic edge filter into a multimode fibre
(50-μm diameter) and into a 300-mm focal length monochro-
mator, which incorporated a 600/mm grating blazed at 500 nm.
A back-illuminated deep-depletion charge-coupled device cam-
era operating at −60 °C was used to detect Raman spectra. We
acquired Raman imaging measurements by raster scanning the
laser beam over cells and collecting a full Raman spectrum at
speed of 0.5 s per pixel, with a pixel resolution of 500 nm.
Multivariate analysis
HCA and principal component analysis (PCA) were per-
formed on Raman spectra of cells. Raman hyperspectral
results were exported to MATLAB 8.2 (The MathWorks,
Natick, MA, USA). Scripts written in-house were used to
perform data preprocessing and multivariate analyses.
Raman spectra without a C–H band at 2850–3000 cm−1 were
treated as the background and were deleted. An impulse noise
filter was used to remove cosmic spikes, and the Raman spec-
tra were interpolated to a reference wavenumber scale. All
spectra were then baseline corrected with a third-order poly-
nomial and were also vector normalised. HCAwas performed
on the regions from 700 to 1800 cm−1 and 2800 to 3050 cm−1
with use ofWard’s clustering in combination with the Pearson
correlation distance. All Raman mean spectra obtained from
HCA were normalised with the phenylalanine band near
1008 cm−1. We calculated Raman difference spectra of cells
by subtracting the mean spectrum of erlotinib-treated cells
from that of control cells for each component identified by
HCA. PCAwas performed on the mean spectra for all subcel-
lular components identified by HCA of both control and
erlotinib-treated cells, and the first three PCs generated denote
the higher variances within the data set [58]. PC1 loadings of
respective subcellular components of control and erlotinib-
treated cells were paired for comparison.
Western blot
Phosphatase inhibitor/buffer mixture II (Sigma-Aldrich,
Munich, Germany) and protease inhibitor cocktail (Roche)
were used to harvest the cells. They were resolved by sodium
dodecyl sulfate–10% polyacrylamide gel electrophoresis, and
transferred to Immobilon-P membranes (Millipore,
Schwalbach am Taunus, Germany). The membranes were
then incubated with antibodies to activate phosphorylated
ERK1 and ERK2 (p-ERK; Cell Signaling Technology,
Danvers, MA, USA), total ERK1 and ERK2 (Cell Signaling
Technology, Danvers, MA, USA), phosphorylated AKT (p-
AKT; Cell Signaling Technology, Danvers, USA), and total
AKT (Cell Signaling Technology, Danvers, USA). Antibodies
were detected with the appropriate anti-mouse horseradish
peroxidase conjugated secondary antibody enhanced by
chemiluminescence (Pierce, Life Technologies, Darmstadt,
Germany), and images were captured with a Versa Doc 5000
imaging system (Bio-Rad, Munich, Germany).
Results and discussion
Downstream signalling and oncogenic mutations
by Western blot
Binding of EGF to EGFR leads to dimerisation of EGFR,
followed by phosphorylation of the EGFR TK domain.
Subsequently, it leads to activation of the RAS machinery,
which in turn activates multiple pathways towards cell
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proliferation (Fig. 1) [59,60]. Erlotinib blocks the receptor
phosphorylation and consequently prevents RAS activation
and inhibits cancer cell proliferation [10,11]. We performed
Western blot experiments to detect the effect of erlotinib on
the phosphorylation of two RAS downstream signalling path-
ways, RAF–ERK and PI3K–AKT, as shown in Fig. 2. It is
expected that BRAFmutation in HT-29 cells and KRASmuta-
tion in SW-480 cells can confer activation of p-ERK and p-
AKT in control cells [61]. This activation is shown in Fig. 2.
Although SW-48 cells harbour wild type KRAS and BRAF,
they also show activation of p-ERK. This is because SW-48
cells carry a mutant EGFR allele [62]. EGF binding to EGFR
increases the ERK and AKT phosphorylation level in these
cancer cells.
Furthermore, no significant difference in p-ERK level was
observed for erlotinib-treated SW-48, HT-29 and SW-480
cells compared with the control. This is perhaps due to the
activating mutations of BRAF in HT-29 cells and KRAS in
SW-480 cells as well as the EGFR mutation in SW-48 cells.
Similar results were observed for the p-AKT level for
erlotinib-treated SW-48 and SW-480 cells. On the other hand,
the p-AKT level was reduced in erlotinib-treated HT-29 cells.
This means that the Western blotting results did not signifi-
cantly discriminate between the KRAS and BRAF status in
these cells. These results are also in agreement with a study
conducted to detect the effect of erlotinib on p-ERK and p-
AKT in a series of pancreatic cancer cell lines with wild-type
and mutated KRAS [63].
Effect of erlotinib on SW-48 cells by Raman spectral
imaging
Erlotinib is a reversible competitive inhibitor of the TK do-
main of EGFR that binds to its adenosine 5′-triphosphate
binding site. To detect the effect of erlotinib binding to the
TK domain, several Raman measurements of SW-48 cells
were performed. Cells were incubated with erlotinib at
10 μg/ml for 12 h. The concentration of erlotinib used in this
study is similar to that detected in the plasma of cancer pa-
tients taking this drug. The oral dosage of erlotinib in clinics is
150 mg/day, and the erlotinib concentration in the plasma was
found to be 2.5–29 μg/ml [64]. No contribution from erlotinib
to the Raman spectra itself was expected because of its low
concentration, which cannot be detected under our experimen-
tal conditions.
We calculated the Raman difference spectrum of SW-48
cells by subtracting the mean spectrum of erlotinib-treated
cells from that of the control cells; the results are presented
in Fig. 3. The difference spectrum shows large spectral chang-
es, which are represented by negative peaks at 1134 cm−1 (C–
C/C–N stretching), 1334 cm−1 (amide III), 1463 cm−1 (C–H
and CH2 bending deformation), 1592 cm
−1 (C=C bending),
1661 cm−1 (amide I), and 2858, 2891, and 2935 cm−1 (C–H
stretching) [42,65,66]. These changes can be attributed to the
changes in proteins, nucleic acids, lipids, and carbohydrates
that are constituents of the cell resulting from erlotinib treat-
ment. Erlotinib-driven biochemical changes of subcellular
components would result in cell cycle arrest and eventually
lead to apoptosis [6,67–69].
These results encouraged us to improve the spatial resolu-
tion of the cell response to erlotinib.We intended to emphasise
the changes of subcellular components in response to erlotinib
treatment. Subcellular organelles were determined by Raman
spectroscopy coupled with HCA. Figure 4 shows a Raman
intensity image of SW-48 cells in the absence of erlotinib
(control) based on the integrated Raman intensities of the C–
H stretching vibration in the 2800–3100-cm−1 region. The size
of the image is 45×45 μm2 (90×90 pixels).
Next, HCAwas performed in the spectral ranges from 700
to 1800 cm−1 and 2800 to 3100 cm−1 in order to construct a
cluster map based on the Raman intensity image (Fig. 4,
panel a); the result is shown in Fig. 4, panel b. The clusters
were then merged to four major subcellular components: plas-
ma membrane, cytoplasm, nucleus, and lipid droplets. This
merging process was based on use of the spectral marker
bands of each cell component. Afterwards, mean spectra of
Fig. 2 Effect of EGF (50 ng/ml for 15 min) and erlotinib (10 μg/ml for
2 h) on ERK and AKT activation in SW-48, HT-29, and SW-480 colon
cancer cells. Cell lysates were resolved by sodium dodecyl sulfate–Poly-
acrylamide gel electrophoresis and Western blot analysis with use of
antibodies that recognise phosphorylated ERK1 and ERK2 (p-Erk 1/2)
and phosphorylated AKT (p-Akt) or total ERK1 and ERK2 (Erk 1/2), and
AKT (Akt)
8324 H.K. Yosef et al.
the four clusters were calculated (Fig. 4, spectra c–f). The
outermost cluster (Fig. 4, spectrum c) is considered to contain
the plasma membrane. However, the plasma membrane is
smaller than the laser spot (less than 1 μm); therefore, the
membrane cluster might contain contributions from the buffer
and cytoplasm (Fig. 4, spectrum d). The mean spectrum of the
nucleus (Fig. 4, spectrum e) contains characteristic Raman
bands such as the stretching vibration of DNA phosphodiester
at 790 cm−1. The spectrum of the cytoplasm (Fig. 4, spectrum
d) and that of the nucleus (Fig. 4, spectrum e) both contain the
Raman spectral band of the ring-breathing mode of phenylal-
anine at 1008 cm−1, which represents their protein constituent.
However, cytoplasm spectra do not contain the DNA marker
band at 790 cm−1 [55–57,70]. The Raman mean spectrum of
lipid droplets (Fig. 4, spectrum f) shows characteristic bands
of the C=O stretching vibration of the ester form of fatty acids
at 1750 cm−1 and the=C―H stretching vibration of unsatu-
rated fatty acids at 3018 cm−1. The spectra of the nucleus and
lipid droplets are consistent with those reported previously
[42,43,49,50].
To monitor the effect of erlotinib on cells, several Raman
measurements of control cells (SW-48) and cells treated with
erlotinib were acquired. Data analysis and HCA were per-
formed for all Raman measurements in ways similar to those
for the data presented in Fig. 4. All Raman mean spectra
obtained from HCA were normalised with the phenylalanine
Fig. 3 Raman difference spectra
of SW-48 cells for control cells
and erlotinib-treated cells in two
spectral regions: a 700–
1800 cm−1 and b 2800–
3100 cm−1. The shading repre-
sents the standard deviation
Fig. 4 a Raman intensity image
constructed in the C–H stretching
region of SW-48 cells. b hierar-
chical cluster analysis (HCA) re-
sults based on the Raman data
shown in a. Mean spectra and the
respective spatial distribution of
HCA clusters: c plasma mem-
brane, d cytoplasm, e nucleus, and
f lipid droplets. The scale bar in a
is 9 μm
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band near 1008 cm−1. We calculated Raman difference spectra
of cellular components by subtracting the mean spectrum of
erlotinib-treated cells from that of control cells for each com-
ponent identified by HCA; the results are shown in Fig. 5.
Obvious spectral changes of the four cellular components
were detected. In addition, the pairwise loading spectra from
PCA of each component displayed clear differences on erlo-
tinib treatment (see Figs. S1–S4). For example, the Raman
difference spectrum of the membrane (Fig. 5, spectrum a) in-
dicates negative peaks at 1231–1259 cm−1 (amide III, and
PO2
−, phospholipid region), 1321 cm−1 (CH2 twisting),
1458–1483 cm−1 (CH deformation), 1642–1688 cm−1 (amide
I), and 2851 and 2891 cm−1 (C–H stretching). These spectral
differences refer to changes in the lipid and protein constitu-
ents of the plasma membrane. The cytoplasm difference spec-
trum (Fig. 5, spectrum b) displays larger changes than that of
the membrane, and shows negative peaks at 1231–1259 cm−1
(amide III), 1321 cm−1 (CH2 twisting), 1455 cm
−1 (C–H de-
formation), 1592 cm−1 (C=C bending), 1642–1688 cm−1 (am-
ide I), and 2851–2950 cm−1 (C–H stretching). In the case of
the nucleus, the Raman difference spectrum (Fig. 5,
spectrum c) reveals clear changes at 1134 cm−1 (C–C/C–N
stretching), 1231–1259 cm−1 (amide III), 1321 cm−1 (CH2
twisting), 1458 cm−1 (C–H deformation), 1592 cm−1 (C=C
bending), 1657–1666 cm−1 (amide I), and 2851–2950 cm−1
(C–H stretching).
The largest changes of all the cell components were ob-
served in the Raman difference spectrum of lipid droplets
(Fig. 5, spectrum d). It exhibits intense positive peaks at
1272 cm−1 (CH3 twisting), 1308 cm
−1 (CH2 twisting),
1446 cm−1 (C–H deformation), 1650–1674 cm−1 (C=C–
stretching vibration of unsaturated fatty acids), 1744 cm−1
(=C–H stretching vibration of unsaturated fatty acids),
2851–2950 cm−1 (CH stretching), and 3016 cm−1 (=C–H
stretching). These strong positive peaks refer to a decrease in
the intensity of the mean spectrum of lipid droplets in
erlotinib-treated cells. This might be produced as a result of
a decrease in the number of lipid droplets in erlotinib-treated
cells. In fact, lipid droplets play a major role in cell prolifera-
tion. It was believed that the only function of lipid droplets is
to store and metabolise lipids. However, it is found that lipid
droplets are also involved in protein storage, degradation, and
trafficking processes [71]. Lipid droplets are also accumu-
lated in cancer cells, and they induce proliferation in co-
lon cancer [72,73]. In addition, lipid droplets decrease in
number or disappear in cells treated with drugs, and the
amount of lipid droplets might have some effect in drug
resistance of tumour cells [74]. Even more, erlotinib treat-
ment results in reducing accumulation of lipid droplets in
human cardiomyocytes [75]. Thus, lipid droplets have be-
come an important target in cancer therapy [72,73]. HCA
images based on Raman measurements of SW-48 cells
show that the number of lipid droplets decreases in cells
treated with erlotinib (Fig. 6b, d) in comparison with con-
trol cells (Fig. 6a, c). Given these facts, we suggest that
the positive peaks of lipid droplets in the difference spec-
trum (Fig. 5d) are produced as a result of reduction of
lipid droplet numbers in erlotinib-treated cells when com-
pared with control cells. In contrast to lipid droplets, the
Raman difference spectra revealed negative peaks for the
membrane, cytoplasm, and nucleus on erlotinib treatment,
Fig. 5 Raman difference spectra of SW-48 cells for control cells and
erlotinib-treated cells for a plasma membrane, b cytoplasm, c nucleus,
and d lipid droplets. The shading represents the standard deviation
Fig. 6 HCA results based on the Raman intensity images of a SW-48
control cells and b SW-48 erlotinib-treated cells. The clusters are shown
in red for plasma membrane, blue for cytoplasm, green for nuclei, and
yellow for lipid droplets. c HCA cluster of lipid droplets from a. d HCA
cluster of lipid droplets from b. The scale bar is 7 μm
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implying that the Raman intensity of these components is
increased in erlotinib-treated cells. This is perhaps due to
an increase in the expression level of proteins during ap-
optosis on erlotinib treatment [68,69,76].
Resistance of oncogenic mutations to erlotinib therapy
by Raman spectral imaging
We applied the experimental conditions used for SW-48 cells
to the other two colon cancer cell lines, HT-29, and SW-480,
which have oncogenic mutations of BRAF (V600E), and
KRAS (G12V), respectively [77]. Figure 7 displays the
Raman difference spectrum of HT-29 cells, which shows rel-
atively few spectral differences when compared with the
Raman difference spectrum of SW-48 cells (Fig. 3). Spectral
changes are observed (Fig. 7) at 1446, 1595–1690, 2851,
2893, and 2935 cm−1. Further clustering of four subcellular
components of HT-29 cells was performed, and the Raman
difference spectra detect some small spectral changes in the
plasma membrane, cytoplasm, nucleus, and lipid droplets, as
indicated in Fig. 8.
In the case of the membrane (Fig. 7, spectrum a), the
Raman difference spectrum shows changes at 1446, 1600–
1660, and 2851–3935 cm−1. The cytoplasm difference spec-
trum (Fig. 7, spectrum b) displays negative spectral changes at
1448, 1650–1674, and 2851–2935 cm−1. In addition, the nu-
cleus difference spectrum (Fig. 7, spectrum c) shows negative
spectral changes at 1095, 1300–1360, 1583, 1650–1690, and
2891–2980 cm−1. Finally, the lipid droplet spectrum (Fig. 7,
spectrum d) exhibits notable changes at 1272, 1595–1690,
1748, and 2851–2935 cm−1. To compare the observed spectral
changes for both SW-48 cells (Fig. 3 or Fig. 5) and HT-29
cells (Fig. 7 or Fig. 8), the same intensity scale is used. HT-29
cells (Figs. 7 and 8), harbouring BRAF mutation, showed a
small response to erlotinib treatment in comparison with SW-
48 cells (Figs. 3, 5). Furthermore, Fig. 9 shows the calculated
Raman difference spectrum of SW-480 cells. The spectrum
reveals no significant spectral changes between control and
erlotinib-treated cells. Thus, the Raman results show that
HT-29 cells (BRAF mutated) and SW-480 cells (KRASmutat-
ed) display a smaller and not significant change, respectively,
on erlotinib treatment.
Fig. 7 Raman difference spectra
of HT-29 cells for control cells
and erlotinib-treated cells in two
spectral regions: a 700–
1800 cm−1 and b 2800–
3100 cm−1 . The shading repre-
sents the standard deviation
Fig. 8 Raman difference spectra of HT-29 cells for control cells and
erlotinib-treated cells for a plasma membrane, b cytoplasm, c nucleus,
and d lipid droplets. The shading represents the standard deviation
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It is worth mentioning that BRAF mutation affects mainly
one signalling pathway for cell proliferation, whereas KRAS
mutation affects multiple pathways (Fig. 1); therefore, the im-
pact of BRAF mutation is less than that of KRAS mutation. In
agreement with the present Raman results, clinical studies on
human patients harbouring BRAF- or KRAS-mutated tumours
have shown a limited response to TK inhibitors
[22,25,29,34,78]. On the other hand, the Western blot results
could not discriminate between erlotinib-treated cells
harbouring wild-type KRAS and BRAF and those with KRAS
and BRAF mutations through monitoring the ERK phosphory-
lation. In addition, the AKT phosphorylation is inhibited only
in cells with BRAF mutations. In Western blot, antibodies are
used to mark single proteins although cellular proteins are high-
ly coupled in protein networks, and monitoring of a single
protein may not reflect the in vivo cellular response to drugs
such as erlotinib. This might explain the differences between
the findings of in vitro drug studies and the drug effect observed
in cancer patients. On the other hand, Raman microscopy re-
flects the overall chemical composition of the cell, and Raman
difference spectra can detect the changes in the whole cell con-
tents, which would be an efficient way to exhibit the overall
cellular and subcellular component changes upon drug
treatment.
Developing a new preclinical method that would predict
the resistance of mutated cancers to therapy can reduce the
cost, time, and effort spent in the new drug discovery process.
It is one step further to increase the accuracy of in vitro drug
evaluation, before these drugs proceed to clinical trials to be
tested on human patients. In fact, clinical trials suffer from
many ethical and economical limitations [5]. Consequently,
increasing the accuracy of in vitro evaluation tests would have
a significant impact on accelerating the process of new anti-
cancer drug evaluation and final approval.
Conclusion
Raman microscopy coupled with clustering analysis such as
HCA can be used to detect the subcellular changes induced by
drug treatment. Raman difference spectra can also emphasise
the oncogenic mutational drug resistance in EGFR-targeted
therapy. Erlotinib resistance in BRAF- and KRAS-mutated co-
lon cancers is clearly reflected in their Raman difference spec-
tra. Cancer cells with wild-type KRAS and BRAF show clear
changes upon erlotinib treatment, whereas BRAF- and KRAS-
mutated cancer cells display a limited change or no significant
changes, respectively. Consistently, clinical studies revealed
that human cancer patients with BRAF- or KRAS-mutated tu-
mours have the worst therapy prognosis. Accordingly, in vitro
Raman imaging is a valuable addition that can enhance the
sensitivity of the preclinical evaluation methods for new anti-
cancer agents.
Acknowledgments We thank Carsten Kötting for helpful discussions.
We also thank Dennis Petersen for his assistance in the PCA. This study
was supported by the Protein Research Unit Ruhr Within Europe (PURE),
theMinistry of Innovation, Science and Research (MIWF) of North Rhine–
Westphalia, Germany, and the Center for Vibrational Microscopy, Europe-
an Regional Development Fund, the European Union, and North Rhine–
Westphalia, Germany, and the Deutsche Forschungsgemeinschaft under
grant number: SFB 642. This study was also supported by a fellowship
to H.K.Y. from the Konrad Adenauer Foundation.
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
Fig. 9 Raman difference spectra
of SW-480 cells for control cells
and erlotinib-treated cells in two
spectral regions: a 700–
1800 cm−1 and b 2800–
3100 cm−1. The shading repre-
sents the standard deviation
8328 H.K. Yosef et al.
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. International Agency for Research on Cancer, World Health
Organization (2014) World cancer report 2014. International
Agency for Research on Cancer, Lyon
2. Fujimoto K (2001) Transforming growth factor-β1 promotes
Invasiveness after cellular transformation with activated Ras in
Intestinal epithelial cells. Exp Cell Res 266:239–249. doi:10.
1006/excr.2000.5229
3. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A,
Taira K, Kawakami Y (2004) Inhibition of growth and invasive
ability of melanoma by inactivation of mutated BRAF with
lentivirus-mediated RNA interference. Oncogene 23:6031–6039.
doi:10.1038/sj.onc.1207812
4. Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E,
Capelinha AF, Duval A, Hamelin R, Machado JC, Schwartz S,
Carneiro F, Seruca R (2007) KRAS and BRAF oncogenic muta-
tions in MSS colorectal carcinoma progression. Oncogene 26:158–
163. doi:10.1038/sj.onc.1209758
5. Zips D, Thames HD, Baumann M (2005) New anticancer agents:
in vitro and in vivo evaluation. In Vivo 19:1–7
6. Goel S, HidalgoM, Perez-Soler R (2007) EGFR inhibitor-mediated
apoptosis in solid tumors. J Exp Ther Oncol 6:305–320
7. Raponi M, Winkler H, Dracopoli NC (2008) KRAS mutations pre-
dict response to EGFR inhibitors. Curr Opin Pharmacol 8:413–418.
doi:10.1016/j.coph.2008.06.006
8. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small
molecule kinase inhibitors. Nat Rev Cancer 9:28–39. doi:10.1038/
nrc2559
9. Dowell J, Minna JD, Kirkpatrick P (2005) Fresh from the pipeline:
Erlotinib hydrochloride. Nat Rev Drug Discov 4:13–14. doi:10.
1038/nrd1612
10. Tang PA, Tsao M-S, Moore MJ (2006) A review of erlotinib and its
clinical use. Expert Opin Pharmacother 7:177–193. doi:10.1517/
14656566.7.2.177
11. Siegel-Lakhai WS (2005) Current knowledge and future directions
of the selective epidermal growth factor receptor inhibitors erlotinib
(Tarceva®) and gefitinib (Iressa®). Oncologist 10:579–589. doi:10.
1634/theoncologist.10-8-579
12. Duckett DR, Cameron MD (2010) Metabolism considerations for
kinase inhibitors in cancer treatment. Expert Opin Drug Metab
Toxicol 6:1175–1193. doi:10.1517/17425255.2010.506873
13. Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del
Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro
G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A,
Iacobelli S, Cognetti F, Buttitta F (2009) Clinical implications of
KRAS mutations in lung cancer patients treated with tyrosine ki-
nase inhibitors: an important role for mutations in minor clones.
Neoplasia 11:1084–1092
14. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S,
Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C,
Mayne K, Trunzer K, Cappuzzo F (2011) Prospective molecular
marker analyses of EGFR and KRAS from a randomized, placebo-
controlled study of erlotinib maintenance therapy in advanced non-
small-cell lung cancer. J Clin Oncol 29:4113–4120. doi:10.1200/
JCO.2010.31.8162
15. Parsons BL,MyersMB (2013)KRASmutant tumor subpopulations
can subvert durable responses to personalized cancer treatments.
Pers Med 10:191–199. doi:10.2217/pme.13.1
16. Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR,
Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM (2006)
Phase II study of erlotinib (OSI-774) in patients with metastatic
colorectal cancer. Br J Cancer 94:1136–1143. doi:10.1038/sj.bjc.
6603055
17. Cox AD, Der CJ (2010) Ras history: The saga continues. Small
GTPases 1:2–27. doi:10.4161/sgtp.1.1.12178
18. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer
Res 49:4682–4689
19. Repasky GA, Chenette EJ, Der CJ (2004) Renewing the conspiracy
theory debate: does Raf function alone tomediate Ras oncogenesis?
Trends Cell Biol 14:639–647. doi:10.1016/j.tcb.2004.09.014
20. Downward J (2003) Targeting RAS signalling pathways in cancer
therapy. Nat Rev Cancer 3:11–22. doi:10.1038/nrc969
21. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman
DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang
DD (2008) Wild-type KRAS is required for panitumumab efficacy
in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–
1634. doi:10.1200/JCO.2007.14.7116
22. Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez
J, Garcia-Aguilar J, Kim J (2012) Prognostic and predictive roles of
KRAS mutation in colorectal cancer. Int J Mol Sci 13:12153–
12168. doi:10.3390/ijms131012153
23. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C,
Moroni M, Veronese S, Siena S, Bardelli A (2007) Oncogenic
activation of the RAS/RAF signaling pathway impairs the response
of metastatic colorectal cancers to anti-epidermal growth factor
receptor antibody therapies. Cancer Res 67:2643–2648. doi:10.
1158/0008-5472.CAN-06-4158
24. Boguski MS, McCormick F (1993) Proteins regulating Ras and its
relatives. Nature 366:643–654. doi:10.1038/366643a0
25. Eklöf V, Wikberg ML, Edin S, Dahlin AM, Jonsson B-A, Öberg Å,
Rutegård J, Palmqvist R (2013) The prognostic role of KRAS,
BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 108:
2153–2163. doi:10.1038/bjc.2013.212
26. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A,
Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R (2004)
The COSMIC (Catalogue of Somatic Mutations in Cancer) data-
base and website. Br J Cancer 91:355–358. doi:10.1038/sj.bjc.
6601894
27. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012.
CA Cancer J Clin 62:10–29. doi:10.3322/caac.20138
28. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer
therapy. J Natl Cancer Inst 93:1062–1074
29. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor
NM, Potter JD, Newcomb PA (2013) KRAS-mutation status in
relation to colorectal cancer survival: the joint impact of correlated
tumour markers. Br J Cancer 108:1757–1764. doi:10.1038/bjc.
2013.118
30. Chong H, Vikis HG, Guan K-L (2003) Mechanisms of regulating
the Raf kinase family. Cell Signal 15:463–469. doi:10.1016/S0898-
6568(02)00139-0
31. Borràs E, Jurado I, Hernan I, GamundiM, DiasM,Martí I, Mañé B,
Arcusa À, Agúndez JA, Blanca M, Carballo M (2011) Clinical
pharmacogenomic testing of KRAS, BRAF and EGFR mutations
by high resolution melting analysis and ultra-deep pyrosequencing.
BMC Cancer 11:406. doi:10.1186/1471-2407-11-406
32. Zebisch A, Troppmair J (2006) Back to the roots: the remarkable
RAF oncogene story. Cell Mol Life Sci 63:1314–1330. doi:10.
1007/s00018-006-6005-y
33. Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson
M, Tzivion G (2007) Raf kinases: Function, regulation and role in
human cancer. Biochim Biophys Acta 1773:1196–1212. doi:10.
1016/j.bbamcr.2007.05.001
34. KaladyMF, DeJulius KL, Sanchez JA, Jarrar A, Liu X,Manilich E,
Skacel M, Church JM (2012) BRAFMutations in colorectal cancer
In vitro prediction of the efficacy of molecularly 8329
are associated with distinct clinical characteristics and worse prog-
nosis. Dis Colon Rectum 55:128–133. doi:10.1097/DCR.
0b013e31823c08b3
35. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM,
Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri
S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton
VEH, YuanW, Li L,WangW, Eigenbrot C, Kaminker JS, Eberhard
DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de
Sauvage FJ, Faham M, Seshagiri S (2010) Diverse somatic muta-
tion patterns and pathway alterations in human cancers. Nature 466:
869–873. doi:10.1038/nature09208
36. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A,
Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman
DM, Janne PA (2014) Noninvasive detection of response and re-
sistance in EGFR-mutant lung cancer using quantitative next-
generation genotyping of cell-free ülasma DNA. Clin Cancer Res
20:1698–1705. doi:10.1158/1078-0432.CCR-13-2482
37. Singh M, Johnson L (2006) Using genetically engineered mouse
models of cancer to aid drug development: an industry perspective.
Clin Cancer Res 12:5312–5328. doi:10.1158/1078-0432.CCR-06-
0437
38. Kucherlapati R (2012) Genetically modified mouse models for bio-
marker discovery and preclinical drug testing. Clin Cancer Res 18:
625–630. doi:10.1158/1078-0432.CCR-11-2021
39. Becher OJ, Holland EC, Sausville EA, Burger AM (2006)
Genetically engineered models have advantages over xenografts
for preclinical studies. Cancer Res 66:3355–3359. doi:10.1158/
0008-5472.CAN-05-3827
40. Notingher I, Hench LL (2006) Raman microspectroscopy: a nonin-
vasive tool for studies of individual living cells in vitro. Expert Rev
Med Devices 3:215–234. doi:10.1586/17434440.3.2.215
41. Popp J, Tuchin VV, Chiou A, Heinemann S (eds) (2011) Handbook
of biophotonics. Volume 2: photonics for health care. Wiley-VCH,
Weinheim
42. Matthäus C, Chernenko T, Newmark JA, Warner CM, Diem M
(2007) Label-free detection of mitochondrial distribution in cells
by nonresonant Raman microspectroscopy. Biophys J 93:668–
673. doi:10.1529/biophysj.106.102061
43. Krafft C, Knetschke T, Funk RHW, Salzer R (2006) Studies on
stress-induced changes at the subcellular level by Raman
microspectroscopic mapping. Anal Chem 78:4424–4429. doi:10.
1021/ac060205b
44. Krafft C, Codrich D, Pelizzo G, Sergo V (2008) Raman and FTIR
microscopic imaging of colon tissue: a comparative study. J
Biophotonics 1:154–169. doi:10.1002/jbio.200710005
45. Mavarani L, Petersen D, El-Mashtoly SF, Mosig A, Tannapfel A,
Kötting C, Gerwert K (2013) Spectral histopathology of colon can-
cer tissue sections by Raman imaging with 532 nm excitation pro-
vides label free annotation of lymphocytes, erythrocytes and prolif-
erating nuclei of cancer cells. Analyst 138:4035–4039. doi:10.
1039/c3an00370a
46. Draux F, Gobinet C, Sulé-Suso J, Trussardi A, Manfait M,
Jeannesson P, Sockalingum GD (2010) Raman spectral imaging
of single cancer cells: probing the impact of sample fixation
methods. Anal Bioanal Chem 397:2727–2737. doi:10.1007/
s00216-010-3759-8
47. Klein K, Gigler AM, Aschenbrenner T, Monetti R, Bunk W,
Jamitzky F, Morfill G, Stark RW, Schlegel J (2012) Label-free
live-cell imaging with confocal Raman microscopy. Biophys J
102:360–368. doi:10.1016/j.bpj.2011.12.027
48. Palonpon AF, Sodeoka M, Fujita K (2013) Molecular imaging of
live cells by Raman microscopy. Curr Opin Chem Biol 17:708–
715. doi:10.1016/j.cbpa.2013.05.021
49. El-Mashtoly SF, Niedieker D, Petersen D, Krauss SD, Freier E,
Maghnouj A, Mosig A, Hahn S, Kötting C, Gerwert K (2014)
Automated Identification of subcellular organelles by coherent
anti-Stokes Raman scattering. Biophys J 106:1910–1920. doi:10.
1016/j.bpj.2014.03.025
50. Krauß SD, Petersen D, Niedieker D, Fricke I, Freier E, El-Mashtoly
SF, Gerwert K, Mosig A (2015) Colocalization of fluorescence and
Raman microscopic images for the identification of subcellular
compartments: a validation study. Analyst. doi:10.1039/
C4AN02153C
51. Dorney J, Bonnier F, Garcia A, Casey A, Chambers G, Byrne HJ
(2012) Identifying and localizing intracellular nanoparticles using
Raman spectroscopy. Analyst 137:1111–1119. doi:10.1039/
c2an15977e
52. Ling J, Weitman SD, Miller MA, Moore RV, Bovik AC (2002)
Direct Raman imaging techniques for study of the subcellular dis-
tribution of a drug. Appl Opt 41:6006. doi:10.1364/AO.41.006006
53. El-Mashtoly SF, Petersen D, Yosef HK, Mosig A, Reinacher-
Schick A, Kötting C, Gerwert K (2014) Label-free imaging of drug
distribution and metabolism in colon cancer cells by Raman mi-
croscopy. Analyst 139:1155–1161. doi:10.1039/c3an01993d
54. Meister K, Niesel J, Schatzschneider U, Metzler-Nolte N, Schmidt
DA, Havenith M (2010) Label-free imaging of metal-carbonyl
complexes in live cells by Raman microspectroscopy. Angew
Chem Int Ed 49:3310–3312. doi:10.1002/anie.201000097
55. Nawaz H, Bonnier F, Knief P, Howe O, Lyng FM, Meade AD,
Byrne HJ (2010) Evaluation of the potential of Raman
microspectroscopy for prediction of chemotherapeutic response to
cisplatin in lung adenocarcinoma. Analyst 135:3070–3076. doi:10.
1039/c0an00541j
56. Nawaz H, Bonnier F, Meade AD, Lyng FM, Byrne HJ (2011)
Comparison of subcellular responses for the evaluation and predic-
tion of the chemotherapeutic response to cisplatin in lung adeno-
carcinoma using Raman spectroscopy. Analyst 136:2450–2463.
doi:10.1039/c1an15104e
57. Nawaz H, Garcia A, Meade AD, Lyng FM, Byrne HJ (2013)
Raman micro spectroscopy study of the interaction of vincristine
with A549 cells supported by expression analysis of bcl-2 protein.
Analyst 138:6177. doi:10.1039/c3an00975k
58. Bonnier F, Knief P, Lim B, Meade AD, Dorney J, Bhattacharya K,
Lyng FM, Byrne HJ (2010) Imaging live cells grown on a three
dimensional collagen matrix using Raman microspectroscopy.
Analyst 135:3169. doi:10.1039/c0an00539h
59. Citri A, Yarden Y (2006) EGF–ERBB signalling: towards the sys-
tems level. Nat Rev Mol Cell Biol 7:505–516. doi:10.1038/
nrm1962
60. Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, Huang Y,
Pelton JG, Shan Y, Shaw DE, Wemmer DE, Groves JT, Kuriyan J
(2013) Conformational coupling across the plasma membrane in
activation of the EGF receptor. Cell 152:543–556. doi:10.1016/j.
cell.2012.12.032
61. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ,
Sandler RS, Kim HJ, Keku TO, Der CJ (2009) KRAS/BRAF mu-
tation status and ERK1/2 activation as biomarkers for MEK1/2
inhibitor therapy in colorectal cancer. Mol Cancer Ther 8:834–
843. doi:10.1158/1535-7163.MCT-08-0972
62. Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T,
Kim J-S, Haverty P, Stawiski E,Modrusan Z,Waldman T, StokoeD
(2013) Identification of mutant K-Ras-dependent phenotypes using
a panel of isogenic cell lines. J Biol Chem 288:2403–2413. doi:10.
1074/jbc.M112.394130
63. Buck E (2006) Inactivation of Akt by the epidermal growth factor
receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and
colorectal tumor cell lines and contributes to erlotinib sensitivity.
Mol Cancer Ther 5:2051–2059. doi:10.1158/1535-7163.MCT-06-
0007
64. Czejka M, Sahmanovic A, Buchner P, Steininger T, Dittrich C
(2013) Disposition of erlotinib and its metabolite OSI420 in a
8330 H.K. Yosef et al.
patient with high bilirubin levels. Case Rep Oncol 6:602–608. doi:
10.1159/000357211
65. Salzer R, Siesler HW (eds) (2009) Infrared and Raman spectroscop-
ic imaging. Wiley, Weinheim
66. DiemM, Chalmers JM, Griffiths PR (eds) (2008) Vibrational spec-
troscopy for medical diagnosis. Wiley, Chichester
67. Huether A, Höpfner M, Sutter AP, Schuppan D, Scherübl H (2005)
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular
cancer cells and enhances chemosensitivity towards cytostatics. J
Hepatol 43:661–669. doi:10.1016/j.jhep.2005.02.040
68. Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH
(2008) Apoptosis-inducing effect of erlotinib is potentiated by 3,3’-
diindolylmethane in vitro and in vivo using an orthotopic model of
pancreatic cancer. Mol Cancer Ther 7:1708–1719. doi:10.1158/
1535-7163.MCT-08-0354
69. Ling Y-H, Lin R, Perez-Soler R (2008) Erlotinib induces
mitochondrial-mediated apoptosis in human H3255 non-small-
cel l lung cancer cel ls with epidermal growth factor
receptorL858R mutation through mitochondrial oxidative
phosphorylation-dependent activation of BAX and BAK. Mol
Pharmacol 74:793–806. doi:10.1124/mol.107.044396
70. Notingher I, Selvakumaran J, Hench LL (2004) New detection
system for toxic agents based on continuous spectroscopic moni-
toring of living cells. Biosens Bioelectron 20:780–789. doi:10.
1016/j.bios.2004.04.008
71. Welte MA (2007) Proteins under new management: lipid droplets
deliver. Trends Cell Biol 17:363–369. doi:10.1016/j.tcb.2007.06.004
72. Qi W, Fitchev PS, Cornwell ML, Greenberg J, Cabe M, Weber CR,
Roy HK, Crawford SE, Savkovic SD (2013) FOXO3 growth inhibi-
tion of colonic cells is dependent on intraepithelial lipid droplet den-
sity. J Biol Chem 288:16274–16281. doi:10.1074/jbc.M113.470617
73. Tirinato L, Liberale C, Di Franco S, Candeloro P, Benfante A, La
Rocca R, Potze L, Marotta R, Ruffilli R, Rajamanickam VP,
Malerba M, De Angelis F, Falqui A, Carbone E, Todaro M,
Medema JP, Stassi G, Di Fabrizio E (2014) Lipid droplets: a new
player in colorectal cancer stem cells unveiled by spectroscopic
imaging. Stem Cells. doi:10.1002/stem.1837
74. Rak S, De Zan T, Stefulj J, Kosović M, Gamulin O, Osmak M
(2014) FTIR spectroscopy reveals lipid droplets in drug resistant
laryngeal carcinoma cells through detection of increased ester vi-
brational bands intensity. Analyst 139:3407. doi:10.1039/
c4an00412d
75. Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM,
Kramer JW, Brown AM, Shell SA, Bacus S (2013) Multi-
parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib,
and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol
272:245–255. doi:10.1016/j.taap.2013.04.027
76. Hülsmann HJ, Rolff J, Bender C, Jarahian M, Korf U,
Herwig R, Fröhlich H, Thomas M, Merk J, Fichtner I,
Sültmann H, Kuner R (2014) Activation of AMP-activated
protein kinase sensitizes lung cancer cells and H1299 xeno-
grafts to erlotinib. Lung Cancer 86:151–157. doi:10.1016/j.
lungcan.2014.09.001
77. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M,
Hektoen M, Lind GE, Lothe RA (2013) Epigenetic and genetic
features of 24 colon cancer cell lines. Oncogenesis 2, e71. doi:10.
1038/oncsis.2013.35
78. Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M,
Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M,
Dubini A, Burgio M, Casanova C, Crinò L, Amadori D, Dazzi C
(2014) Gene mutation analysis in EGFR wild type NSCLC respon-
sive to erlotinib: are there features to guide patient selection? Int J
Mol Sci 16:747–757. doi:10.3390/ijms16010747
In vitro prediction of the efficacy of molecularly 8331
